TY - JOUR A1 - Caliskan, Aylin A1 - Crouch, Samantha A. W. A1 - Giddins, Sara A1 - Dandekar, Thomas A1 - Dangwal, Seema T1 - Progeria and aging — Omics based comparative analysis JF - Biomedicines N2 - Since ancient times aging has also been regarded as a disease, and humankind has always strived to extend the natural lifespan. Analyzing the genes involved in aging and disease allows for finding important indicators and biological markers for pathologies and possible therapeutic targets. An example of the use of omics technologies is the research regarding aging and the rare and fatal premature aging syndrome progeria (Hutchinson-Gilford progeria syndrome, HGPS). In our study, we focused on the in silico analysis of differentially expressed genes (DEGs) in progeria and aging, using a publicly available RNA-Seq dataset (GEO dataset GSE113957) and a variety of bioinformatics tools. Despite the GSE113957 RNA-Seq dataset being well-known and frequently analyzed, the RNA-Seq data shared by Fleischer et al. is far from exhausted and reusing and repurposing the data still reveals new insights. By analyzing the literature citing the use of the dataset and subsequently conducting a comparative analysis comparing the RNA-Seq data analyses of different subsets of the dataset (healthy children, nonagenarians and progeria patients), we identified several genes involved in both natural aging and progeria (KRT8, KRT18, ACKR4, CCL2, UCP2, ADAMTS15, ACTN4P1, WNT16, IGFBP2). Further analyzing these genes and the pathways involved indicated their possible roles in aging, suggesting the need for further in vitro and in vivo research. In this paper, we (1) compare “normal aging” (nonagenarians vs. healthy children) and progeria (HGPS patients vs. healthy children), (2) enlist genes possibly involved in both the natural aging process and progeria, including the first mention of IGFBP2 in progeria, (3) predict miRNAs and interactomes for WNT16 (hsa-mir-181a-5p), UCP2 (hsa-mir-26a-5p and hsa-mir-124-3p), and IGFBP2 (hsa-mir-124-3p, hsa-mir-126-3p, and hsa-mir-27b-3p), (4) demonstrate the compatibility of well-established R packages for RNA-Seq analysis for researchers interested but not yet familiar with this kind of analysis, and (5) present comparative proteomics analyses to show an association between our RNA-Seq data analyses and corresponding changes in protein expression. KW - progeria KW - aging KW - omics KW - RNA sequencing KW - bioinformatics KW - sun exposure KW - HGPS KW - IGFBP2 KW - ACKR4 KW - WNT Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-289868 SN - 2227-9059 VL - 10 IS - 10 ER - TY - THES A1 - Alonso Cañizal, Maria Consuelo T1 - Detection of ligand dependent Frizzled conformational changes T1 - Nachweis von Liganden-abhängigen Frizzled Konformationsänderungen N2 - Frizzled (FZD) are highly conserved receptors that belong to class F of the G protein-coupled receptor (GPCR) superfamily. They are involved in a great variety of processes during embryonic development, organogenesis, and adult tissue homeostasis. In particular, FZD5 is an important therapeutic target due to its involvement in several pathologies, such as tumorigenesis. Nevertheless, little is known regarding the activation of FZD receptors and the signal initiation, and their GPCR nature has been debated. In order to investigate the activation mechanism of these receptors, FRET (Förster Resonance Energy Transfer)-based biosensors for FZD5 have been developed and characterized. A cyan fluorescent protein (CFP) was fused to the C-terminus of the receptor and the specific FlAsH-binding sequence (CCPGCC) was inserted within the 2nd or the 3rd intracellular loop. Single-cell FRET experiments performed using one of these sensors, V5-mFZD5-FlAsH436-CFP, reported structural rearrangements in FZD5 upon stimulation with the endogenous ligand WNT-5A. These movements are similar to those observed in other GPCRs using the same technique, which suggests an activation mechanism for FZD reminiscent of GPCRs. Furthermore, stimulation of the FZD5 FRET-based sensor with various recombinant WNT proteins in a microplate FRET reader allowed to obtain concentration-response curves for several ligands, being possible to distinguish between full and partial agonists. This technology allowed to address the selectivity between WNTs and FZD5 using a full-length receptor in living cells. In addition, G protein FRET-based sensors revealed that WNT-5A specifically induced Gαq activation mediated by FZD5, but not Gαi activation. Other WNT proteins were also able to induce Gαq activation, but with lower efficacy than WNT-5A. In addition, a dual DAG/calcium sensor further showed that WNT-5A stimulation led to the activation of the Gαq-dependent signaling pathway mediated by FZD5, which outcome was the activation of Protein Kinase C (PKC) and the release of intracellular calcium. Altogether, these data provide evidence that the activation process of FZD5 resembles the general characteristics of class A and B GPCR activation, and this receptor also mediates the activation of the heterotrimeric Gαq protein and its downstream signaling pathway. In addition, the FZD5 receptor FRET-based sensor provides a valuable tool to characterize the pharmacological properties of WNTs and other potential ligands for this receptor. N2 - Frizzled (FZD) sind hochkonservierte Rezeptoren welche zur Klasse F der G- Protein-gekoppelte Rezeptor Superfamilie gehören. Diese haben wichtige Funktionen in verschiedenen physiologischen Prozessen wie zum Beispiel Embryonalentwicklung, Organogenese und adulte Gewebe-homöostase. FZD5 ist aufgrund seiner Beteiligung an verschiedenen pathologischen Prozessen wie der Tumorgenese ein wichtiges therapeutisches Ziel. Jedoch ist über die Aktivierung und Signalauslösung der FZD Rezeptoren sehr wenig bekannt und deren GPCR Eigenschaften sind umstritten. Um den Aktivierungsmechanismus dieser Rezeptoren zu untersuchen, wurden FRET (Förster Resonance Energy Transfer)-basierte FZD5 Biosensoren entwickelt und charakterisiert. Ein cyan fluoreszierendes Protein (CFP) wurde an den C-Terminus des Rezeptors fusioniert und die FlAsH-bindende Sequenz (CCPGCC) wurde im 2. oder 3. intrazellulären Loop eingefügt. Einzel-zell FRET Versuche mit dem Sensor V5-mFZD5-FlAsH436-CFP haben gezeigt, dass Stimulation mit dem endogenen Ligand WNT-5A zur FZD5 Konformationsänderungen führt. Diese Konformationsänderungen sind ähnlich wie bei anderen GPCRs, was darauf hinweist, dass der FZD Aktivierungsmechanismus vergleichbar mit dem von GPCRs ist. Außerdem wurde der FZD5 FRET-basierter Sensor mit verschiedenen rekombinierten WNT Proteinen stimuliert und mit einem FRET-Platten Reader gemessen, was die Erstellung von Konzentrations - Wirkungskurven und die Unterscheidung zwischen Voll- und Partialagonisten ermöglichte. Diese Methode erlaubte es, die Selektivität zwischen WNTs und FZD5 mittels des Volllängenrezeptors in lebenden Zellen zu untersuchen. Zudem haben G-Protein FRET-basierte Sensoren gezeigt, dass WNT-5A die FZD5 vermittelte Gαq Aktivierung jedoch nicht die Gαi Aktivierung spezifisch induziert. Andere WNT Proteine können auch die Gαq Aktivierung induzieren aber mit geringerer Effizienz als WNT-5A. Ein doppelter DAG/Calcium Sensor hat zudem gezeigt, dass WNT-5A Stimulation zu einer durch FZD5 vermittelten Aktivierung der Gαq-abhängigen Signaltransduktionkaskade führt, was zur Aktivierung der Protein Kinase C (PKC) und zur Freisetzung intrazellulären Calciums führt. Zusammenfassend wurde in der vorliegenden Arbeit die Ähnlichkeit des FZD5 Rezeptors zur Klasse A und B der GPCRs bezüglich allgemeinen Eigenschaften und Aktivierung verdeutlicht. Zudem vermittelt dieser Rezeptor die Aktivierung der Gαq-abhängigen Signaltransduktionkaskade. Ein FZD5 Rezeptor FRET-basierter Sensor stellt ein wertvolles Werkzeug zur pharmakologischen Charakterisierung der WNTs und anderer potentiellen FZD5 Liganden dar. KW - Fluoreszenz-Resonanz-Energie-Transfer KW - Wnt-Proteine KW - Frizzled 5 KW - WNT KW - FRET Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-178335 ER - TY - JOUR A1 - van Dinther, Maarten A1 - Zhang, Juan A1 - Weidauer, Stella E. A1 - Boschert, Verena A1 - Muth, Eva-Maria A1 - Knappik, Achim A1 - de Gorter, David J. J. A1 - van Kasteren, Puck B. A1 - Frisch, Christian A1 - Müller, Thomas D. A1 - ten Dijke, Peter T1 - Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling JF - PLoS ONE N2 - Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of osteoporosis. The exact molecular mechanism by which Sclerostin exerts its antagonistic effects on Wnt signaling in bone forming osteoblasts remains unclear. Here we show that Wnt3a-induced transcriptional responses and induction of alkaline phosphatase activity, an early marker of osteoblast differentiation, require the Wnt co-receptors LRP5 and LRP6. Unlike Dickkopf1 (DKK1), Sclerostin does not inhibit Wnt-3a-induced phosphorylation of LRP5 at serine 1503 or LRP6 at serine 1490. Affinity labeling of cell surface proteins with \([^{125} I]\) Sclerostin identified LRP6 as the main specific Sclerostin receptor in multiple mesenchymal cell lines. When cells were challenged with Sclerostin fused to recombinant green fluorescent protein (GFP) this was internalized, likely via a Clathrin-dependent process, and subsequently degraded in a temperature and proteasome-dependent manner. Ectopic expression of LRP6 greatly enhanced binding and cellular uptake of Sclerostin-GFP, which was reduced by the addition of an excess of non-GFP-fused Sclerostin. Finally, an anti-Sclerostin antibody inhibited the internalization of Sclerostin-GFP and binding of Sclerostin to LRP6. Moreover, this antibody attenuated the antagonistic activity of Sclerostin on canonical Wnt-induced responses. KW - gene KW - rat model KW - Dickkopf proteins KW - postmenopausal osteoporosis KW - increases bone-formation KW - WNT KW - LRP6 KW - density KW - receptor KW - ligand Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130981 VL - 8 IS - 4 ER -